InVivoPlus anti-mouse PD-1 (CD279)

Grasselly C, Denis M, Bourguignon A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018,9:2100. doi: 10.3389/fimmu.2018.02100

Triplett TA, Garrison KC, Marshall N, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol. 2018,36(8):758-764. doi: 10.1038/nbt.4180

Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016,22(12):1402-1410. doi: 10.1038/nm.4200

Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015,162(6):1257-70. doi: 10.1016/j.cell.2015.08.015

Ngiow SF, Young A, Jacquelot N, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015,75(18):3800-11. doi: 10.1158/0008-5472.CAN-15-1082

Zander RA, Obeng-Adjei N, Guthmiller JJ, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015,17(5):628-41. doi: 10.1016/j.chom.2015.03.007

Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015,75(11):2232-42. doi: 10.1158/0008-5472.CAN-14-3511

Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015,520(7547):373-7. doi: 10.1038/nature14292

Evans EE, Jonason AS Jr, Bussler H, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015,3(6):689-701. doi: 10.1158/2326-6066.CIR-14-0171

Mittal D, Young A, Stannard K, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014,74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0957